Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

The Effect of taVNS and Upper GI Motility

2 de junho de 2026 atualizado por: Daniel Keszthelyi

The Effect of Non-invasive Transauricular Vagus Nerve Stimulation on Upper Gastrointestinal Motility in Healthy Individuals

This single-center randomized controlled cross-over trial aims to investigate the effect of transcutaneous auricular vagus nerve stimulation on upper gastrointestinal motility in healthy individuals.

The primary aim of this study is to assess the impact of tVNS on gut motor function, with regards to its potential to induce phase III contractions in the upper GI tract.

Secondary objectives include:

  • To study the effect of tVNS on other parameters characterizing upper GI motility such as the number of duodenal phase III contractions, gastric and duodenal phase MMCs, amplitude of antral contractions and motility index
  • To study the effect of tVNS on plasma levels of motilin and PP
  • To evaluate the effect of tVNS on parameters related to autonomic outflow, using a Shimmer3 GSR Sensor for heart rate variability and skin conductance.
  • To compare the results of the measurements of antroduodenal manometry with measurements of Gastric Alimetry

Participants will undergo tVNS (applied to the cymba conchae of the left ear) alternating with sham stimulation (using a non-conducting electrode) in a blinded, pre-randomized fashion, using two 4-hour blocks during an 8-hour fasted antroduodenal manometry recording period. Optionally, participants may simultaneously also undergo body surface gastric mapping using the Gastric Alimetry system.

Visão geral do estudo

Descrição detalhada

Visit 1 (screening visit) Following written informed consent, the medical history of each subject will be checked during a structured interview. A pregnancy will be excluded by a urine test (due to the use or fluoroscopy during insertion of the manometry catheter) and a 12-lead ECG will be performed at the end of the screening visit. The rationale for this is to ensure no evidence of cardiac conduction disorders and an additional safety step to ensure no cardiac dysrhythmic affect with tVNS use. All information obtained during the screening visit will be recorded in using an electronic CRF provided by Castor EDC, provided by the Clinical Trial Centre Maastricht (CTCM).

Visit 2 (test day) Participants will arrive after an overnight fast at the GI physiology unit of the Maastricht University Medical Center, where a trained and experienced nurse will insert an antroduodenal manometry catheter through the nose into the duodenum under fluoroscopy control and supervision of a gastroenterologist (as per routine clinical procedure). Using this catheter, stomach and duodenum motility patterns will be recorded for 8 hours. After the manometry is inserted, the tVNS device will be connected with an electrode which delivers stimulation transcutaneous in the outer ear. Participants will receive two types of stimulation (i.e. tVNS vs sham) in 2 blocks of 4 hours during the 8-hour registration period. The order of stimulation applied is randomized. Gastric phase III contractions generally occur every 90 minutes, so the 4-hour period is considered sufficient to detect two phase III contractions considered sufficient to detect the two phase III contractions.(10)

An iv catheter will be inserted to draw blood during the 8-hour registration period. Blood samples, each witch a maximum volume of 10 mL, will be taken every 30 minutes to measure motilin and PP as surrogate markers of vagal efferent influence on GI motor function. In addition, autonomic parameters will be registered during the entire test period, using a Shimmer3 GSR sensor. After the 8-hour test period, the manometry catheter, the electrodes of the tVNS device and the iv cannula are removed.

Additionally, participants may opt to take part in a body surface gastric mapping assessment. This non-invasive, electrophysiological measurement is performed using the Gastric Alimetry system, which involves placing a large adhesive patch with multiple electrodes on the upper abdomen. The system records gastric myoelectrical activity over time, providing insight into gastric motility patterns. The measurement is conducted concurrently with the manometry registration period.

Tipo de estudo

Intervencional

Inscrição (Estimado)

12

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Limburg
      • Maastricht, Limburg, Holanda, 6229ER
        • Recrutamento
        • Maastricht University

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto

Aceita Voluntários Saudáveis

Sim

Descrição

Inclusion Criteria:

  • Healthy participants (defined as those without a pre-existing medical comorbidity, including those without a history of cardiac arrhythmia).
  • Age between 18 and 55 years.
  • Ability to understand and speak the Dutch language.

Exclusion Criteria:

  • Pregnancy or lactation.
  • Use of any substances (such as medication or recreational drugs) influencing gastrointestinal motility
  • Not meeting the inclusion criteria above.
  • Students and employees of Maastricht University are not precluded from participation, unless they have a direct personal, professional of hierarchical position with regards to any of the study team members or their department.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Outro
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição cruzada
  • Mascaramento: Triplo

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Transcutaneous Auricular Vagal Nerve Stimulation
TaVNS
taVNS will be provided during a 4-hour block of the 8-hour fasted antroduodenal manometry recording period.
Comparador de Placebo: Sham stimulation
Sham stimulation with a non-conducting electrode
Sham stimulation will be provided during a 4-hour block of the 8-hour fasted antroduodenal manometry recording period.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
A clinically meaningful increase in phase III contractions
Prazo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
A clinically meaningful increase in the number of phase III contractions of antral origin in the fasted period during the tVNS stimulation compared to the sham stimulation.
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
A clinically relevant increase in other upper GI motility parameters
Prazo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
A clinically relevant increase in other parameters characterizing upper GI motility such as the number of duodenal phase III contractions, gastric and duodenal phase MMCs, amplitude of antral contractions and motility index
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Concentration of plasma motilin and pancreatic polypeptide
Prazo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Changes in plasma motilin and pancreatic polypeptide following taVNS vs. sham stimulation
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Autonomic response: heart rate variability
Prazo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Changes in heart rate variability measured continuously using a Shimmer3 GSR sensor
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Electrodermal response: skin conductance
Prazo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Changes in skin conductance following taVNS vs sham stimulation, assessed continuously using a Shimmer3 GSR sensor.
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Agreement between gastric motility measurements obtained by antroduodenal manometry and Gastric Alimetry
Prazo: Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)
Agreement between antroduodenal manometry and Gastric Alimetry measurements obtained simultaneously.
Assessed during one single test day, from pre-intervention baseline to post-stimulation (approximately 8-9 hours)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Daniel Keszthelyi, MD, PhD, Maastricht University Medical Center

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

25 de fevereiro de 2025

Conclusão Primária (Estimado)

1 de junho de 2026

Conclusão do estudo (Estimado)

1 de junho de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

26 de maio de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

2 de junho de 2026

Primeira postagem (Real)

8 de junho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

8 de junho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de junho de 2026

Última verificação

1 de junho de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever